https://beonemedaffairs.kinsta.cloud/us/publication/the-concomitant-of-non-classical-stereotactic-body-radiotherapy-with-tislelizumab-based-on-multidisciplinary-modalities-for-leiomyosarcoma-a-case-report/ 2025-04-28T19:05:37+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/peripheral-neuropathy-in-the-phase-3-aspen-study-of-bruton-tyrosine-kinase-inhibitors-for-waldenstrom-macroglobulinemia/ 2025-04-28T19:08:14+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/perioperative-tislelizumab-plus-neoadjuvant-chemotherapy-for-patients-with-resectable-non-small-cell-lung-cancer-rationale-315-an-interim-analysis-of-a-randomised-clinical-trial/ 2025-04-28T19:10:29+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/a-randomized-placebo-controlled-trial-of-the-btk-inhibitor-zanubrutinib-in-hospitalized-patients-with-covid-19-respiratory-distress-immune-biomarker-and-clinical-findings/ 2025-04-28T19:12:07+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/acquired-mutations-in-patients-with-relapsed-refractory-cll-who-progressed-in-the-alpine-study/ 2025-04-28T19:12:49+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/comparative-effectiveness-and-safety-of-tislelizumab-versus-other-anti-pd-l1-agents-in-first-and-subsequent-lines-in-locally-advanced-or-metastatic-non-small-cell-lung-cancer-syste/ 2025-04-28T19:13:42+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/first-line-tislelizumab-plus-chemotherapy-for-advanced-gastric-cancer-with-programmed-death-ligand-1-expression-%e2%89%a5-1-a-retrospective-analysis-of-rationale-305/ 2025-04-28T19:15:37+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/first-line-tislelizumab-plus-chemotherapy-for-esophageal-squamous-cell-carcinoma-with-programmed-death-ligand-1-expression-%e2%89%a5-1-a-retrospective-analysis-of-rationale-306/ 2025-04-28T19:16:21+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/notch1-mutation-and-survival-analysis-of-tislelizumab-in-advanced-or-metastatic-esophageal-squamous-cell-carcinoma-a-biomarker-analysis-from-the-randomized-phase-iii-rationale-302-trial/ 2025-04-28T19:17:29+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/number-needed-to-treat-and-associated-cost-analysis-of-zanubrutinib-vs-ibrutinib-in-chronic-lymphocytic-leukemia/ 2025-04-28T19:18:09+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/zanubrutinib-in-japanese-treatment-naive-and-relapsed-refractory-patients-with-waldenstrom-macroglobulinemia-and-cll-sll/ 2025-04-28T19:19:12+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/cardiovascular-events-reported-in-patients-with-b-cell-malignancies-treated-with-zanubrutinib/ 2025-04-28T19:25:40+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/saffron-104-a-phase-ib-ii-study-of-sitravatinib-alone-or-with-tislelizumab-in-advanced-hepatocellular-carcinoma-and-gastric-cancer-gastroesophageal-junction-cancer/ 2025-04-28T19:26:54+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/second-line-tislelizumab-versus-chemotherapy-in-japanese-patients-with-advanced-or-metastatic-esophageal-squamous-cell-carcinoma-subgroup-analysis-from-rationale-302/ 2025-04-28T19:27:44+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/co-enrichment-of-cd8-positive-t-cells-and-macrophages-is-associated-with-clinical-benefit-of-tislelizumab-in-solid-tumors/ 2025-04-28T19:28:16+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/tislelizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-as-first-line-treatment-for-advanced-or-metastatic-oesophageal-squamous-cell-carcinoma-rationale-306-a-global-randomised-placebo-co/ 2025-04-28T19:29:27+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/zanubrutinib-alone-and-in-combination-with-tislelizumab-for-the-treatment-of-richter-transformation-of-chronic-lymphocytic-leukemia-2/ 2025-04-28T19:30:22+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/biomarker-analysis-of-the-aspen-study-comparing-zanubrutinib-to-ibrutinib-in-patients-with-waldenstrom-macroglobulinemia/ 2025-04-28T19:31:19+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/a-highly-selective-pi3k%ce%b4-inhibitor-bgb-10188-shows-superior-preclinical-anti-tumor-activities-and-decreased-on-target-side-effects-on-colon/ 2025-04-28T19:32:29+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/phase-1-2-study-of-the-pd-l1-inhibitor-bgb-a333-alone-and-in-combination-with-the-pd-1-inhibitor-tislelizumab-in-patients-with-advanced-solid-tumours/ 2025-04-28T19:34:56+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/sars-cov-2-neutralising-antibody-bgb-dxp593-in-mild-to-moderate-covid-19-a-multicentre-randomised-double-blind-phase-2-trial/ 2025-04-28T19:35:19+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/phase-1b-study-to-assess-the-safety-tolerability-and-clinical-activity-of-pamiparib-in-combination-with-temozolomide-in-patients-with-locally-advanced-or-metastatic-solid-tumors/ 2025-04-28T19:39:16+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/pamiparib-in-combination-with-tislelizumab-in-patients-with-advanced-solid-tumours-results-from-the-dose-expansion-stage-of-a-multicentre-open-label-phase-i-trial/ 2025-04-28T19:40:47+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/saffron-103-a-phase-ib-study-of-sitravatinib-plus-tislelizumab-in-anti-pd-l1-refractory-resistant-advanced-melanoma/ 2025-04-28T19:41:32+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/discovery-of-the-clinical-candidate-sonrotoclax-bgb-11417-a-highly-potent-and-selective-inhibitor-for-both-wt-and-g101v-mutant-bcl-2/ 2025-04-28T19:43:48+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/sonrotoclax-overcomes-bcl2-g101v-mutation-induced-venetoclax-resistance-in-preclinical-models-of-hematologic-malignancy/ 2025-04-28T19:44:48+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/clinical-dose-rationale-of-tislelizumab-in-patients-with-solid-or-hematological-advanced-tumors/ 2025-04-28T19:46:54+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/effects-of-tislelizumab-on-health-related-quality-of-life-in-patients-with-recurrent-or-metastatic-nasopharyngeal-cancer/ 2025-04-28T19:47:40+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/tislelizumab-in-previously-treated-locally-advanced-unresectable-metastatic-microsatellite-instability-high-mismatch-repair-deficient-solid-tumors/ 2025-04-28T19:49:00+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/tislelizumab-plus-chemotherapy-as-first-line-treatment-of-locally-advanced-or-metastatic-nonsquamous-non-small-cell-lung-cancer-final-analysis-of-rationale-304-a-randomized-phase-iii-trial/ 2025-04-28T19:50:00+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/tislelizumab-plus-chemotherapy-versus-chemotherapy-alone-as-first-line-treatment-for-advanced-squamous-non-small-cell-lung-cancer-final-analysis-of-the-randomized-phase-iii-rationale-307-trial/ 2025-04-28T19:50:44+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/tislelizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-as-first-line-treatment-for-advanced-gastric-or-gastro-oesophageal-junction-adenocarcinoma-rationale-305-randomised-double-blind-phas/ 2025-04-28T19:51:46+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/tislelizumab-plus-platinum-and-etoposide-versus-placebo-plus-platinum-and-etoposide-as-first-line-treatment-for-extensive-stage-small-cell-lung-cancer-rationale-312-a-multicenter-double-blind-pla/ 2025-04-28T19:52:28+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/response-characteristics-of-tislelizumab-combined-with-chemotherapy-in-first-line-treatment-of-locally-advanced-or-metastatic-non-squamous-non-small-cell-lung-cancer/ 2025-04-28T19:53:30+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/saffron-103-a-phase-1b-study-of-the-safety-and-efficacy-of-sitravatinib-combined-with-tislelizumab-in-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer/ 2025-04-28T19:54:11+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/the-effects-of-tislelizumab-treatment-on-the-health-related-quality-of-life-of-patients-with-advanced-non-small-cell-lung-cancer/ 2025-04-28T19:54:59+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/tislelizumab-plus-chemotherapy-as-first-line-treatment-for-recurrent-or-metastatic-nasopharyngeal-cancer-a-multicenter-phase-3-trial-rationale-309/ 2025-04-28T19:55:37+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/tislelizumab-vs-sorafenib-as-first-line-treatment-for-unresectable-hepatocellular-carcinoma-a-phase-3-randomized-clinical-trial/ 2025-04-28T19:56:34+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/characterization-of-zanubrutinib-safety-and-tolerability-profile-and-comparison-with-ibrutinib-safety-profile-in-patients-with-b-cell-malignancies-post-hoc-analysis-of-a-large-clinical-trial-safety-d/ 2025-04-28T19:59:08+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/delphi-consensus-recommendations-on-treatment-for-advanced-stage-marginal-zone-lymphoma-in-south-korea/ 2025-04-28T19:59:32+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/genomic-landscape-of-patients-in-a-phase-ii-study-of-zanubrutinib-in-ibrutinib-and-or-acalabrutinib-intolerant-patients-with-b-cell-malignancies/ 2025-04-28T20:00:53+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/health-related-quality-of-life-in-patients-with-waldenstrom-macroglobulinemia-results-from-the-aspen-trial/ 2025-04-28T20:01:42+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/improved-efficacy-and-safety-of-zanubrutinib-versus-ibrutinib-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-r-r-cll-in-china-a-subgroup-of-alpine/ 2025-04-28T20:02:33+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/matching-adjusted-indirect-comparisons-of-zanubrutinib-magnolia-bgb-3111-au-003-versus-ibrutinib-pcyc-1121-and-rituximab-chronos-3-in-relapsed-refractory-marginal-zone-lymphoma/ 2025-04-28T20:03:17+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/patient-reported-outcomes-in-patients-with-relapsed-or-refractory-follicular-lymphoma-treated-with-zanubrutinib-plus-obinutuzumab-versus-obinutuzumab-monotherapy-results-from-the-rosewood-trial/ 2025-04-28T20:03:58+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/plain-language-summary-of-zanubrutinib-or-ibrutinib-in-chronic-lymphocytic-leukemia-that-is-resistant-to-treatment-or-has-come-back-after-treatment-2/ 2025-04-28T20:05:34+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/real-world-treatment-patterns-and-outcomes-for-patients-with-cll-using-the-australian-pharmaceutical-benefits-scheme-pbs-dataset/ 2025-04-28T20:06:18+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/similar-efficacy-of-ibrutinib-arms-across-alpine-and-elevate-rr-trials-in-relapsed-refractory-chronic-lymphocytic-leukemia-a-matching-adjusted-indirect-comparison/ 2025-04-28T20:06:57+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/sustained-benefit-of-zanubrutinib-vs-ibrutinib-in-patients-with-r-r-cll-sll-final-comparative-analysis-of-alpine/ 2025-04-28T20:07:39+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/tislelizumab-versus-sorafenib-in-first-line-treatment-of-unresectable-hepatocellular-carcinoma-impact-on-health-related-quality-of-life-in-rationale-301-study/ 2025-04-28T20:08:34+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/zanubrutinib-is-effective-in-non-germinal-center-b-cell-like-diffuse-large-b-cell-lymphoma-with-mutated-cd79b-high-tcl1a-expression-or-over-expressed-myc-bcl-2/ 2025-04-28T20:09:13+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/a-phase-1-open-label-fixed-sequence-drug-drug-interaction-study-of-zanubrutinib-with-rifabutin-in-healthy-volunteers/ 2025-04-28T20:09:48+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/health-related-quality-of-life-in-treatment-naive-cll-sll-patients-treated-with-zanubrutinib-versus-bendamustine-plus-rituximab/ 2025-04-28T20:11:07+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/health-related-quality-of-life-outcomes-associated-with-zanubrutinib-versus-ibrutinib-monotherapy-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma-resu/ 2025-04-28T20:11:57+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/indirect-comparisons-of-efficacy-of-zanubrutinib-versus-orelabrutinib-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-or-relapsed-or-refractory-mantle-c/ 2025-04-28T20:12:59+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/molecular-associations-of-response-to-the-new-generation-btk-inhibitor-zanubrutinib-in-marginal-zone-lymphoma/ 2025-04-28T20:14:03+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/long-term-outcomes-of-second-line-versus-later-line-zanubrutinib-treatment-in-patients-with-relapsed-refractory-mantle-cell-lymphoma-an-updated-pooled-analysis/ 2025-04-28T20:14:33+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/plain-language-summary-of-zanubrutinib-or-ibrutinib-in-chronic-lymphocytic-leukemia-that-is-resistant-to-treatment-or-has-come-back-after-treatment/ 2025-04-28T20:15:15+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/rosewood-a-phase-ii-randomized-study-of-zanubrutinib-plus-obinutuzumab-versus-obinutuzumab-monotherapy-in-patients-with-relapsed-or-refractory-follicular-lymphoma/ 2025-04-28T20:15:58+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/safety-and-efficacy-of-zanubrutinib-in-relapsed-refractory-marginal-zone-lymphoma-final-analysis-of-the-magnolia-study/ 2025-04-28T20:16:33+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/zanubrutinib-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-final-results-and-correlative-analysis-of-lymphocytosis/ 2025-04-28T20:17:27+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/zanubrutinib-in-patients-with-relapsed-refractory-hairy-cell-leukemia/ 2025-04-28T20:17:55+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/zanubrutinib-in-patients-with-treatment-naive-or-relapsed-refractory-waldenstrom-macroglobulinemia-an-expanded-access-study-of-50-patients-in-the-united-states/ 2025-04-28T20:18:26+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/zanubrutinib-versus-ibrutinib-in-symptomatic-waldenstrom-macroglobulinemia-final-analysis-from-the-randomized-phase-iii-aspen-study/ 2025-04-28T20:19:20+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/zanubrutinib-versus-bendamustine-and-rituximab-in-patients-with-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-median-5-year-follow-up-of-sequoia/ 2025-04-29T09:52:20+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/tislelizumab-versus-docetaxel-in-patients-with-previously-treated-advanced-nsclc-rationale-303-a-phase-3-open-label-randomized-controlled-trial/ 2025-04-29T09:54:57+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/comparative-efficacy-of-bruton-tyrosine-kinase-inhibitors-in-high-risk-relapsed-refractory-cll-a-network-meta-analysis/ 2025-07-29T15:42:53+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/efficacy-of-zanubrutinib-versus-acalabrutinib-for-relapsed-or-refractory-chronic-lymphocytic-leukemia-a-matching-adjusted-indirect-comparison/ 2025-09-22T10:30:49+00:00 https://beonemedaffairs.kinsta.cloud/us/publication/zanubrutinib-for-the-treatment-of-patients-with-del17p-and-or-tp53-cll-sll-infographic/ 2026-02-12T21:33:35+00:00